Explore the vast range of titles available.

Purpose Cancer cells are known to exhibit a cancer-associated fibroblast (CAF)-dependent invasive mode in the presence of CAFs. The purpose of this study was to investigate whether intrinsic factors of gastric cancer cells influence the CAF-dependent invasive mode of cancer cells. Methods We observed dynamic movement of CAFs, and cancer cells, by time-lapse imaging of 2-D and 3-D collagen invasion models, and evaluated invasion modes of gastric cancer cell lines (MKN-7, MKN-45, and HSC44PE). We further examined whether modification of invasive capacity of CAFs can alter invasive mode of MKN-7, and HSC44PE cells. Results When MKN-7 and MKN-45 cells were co-cultured with CAFs, CAFs first invade collagen matrix followed by cancer cells (CAF-dependent invasion), whereas HSC44PE cells invaded collagen matrix independent of CAFs’ invasion. Overexpression or suppression of podoplanin in CAFs, respectively, increased or decreased the invasive capacity of CAFs, and significantly increased or decreased the number of invading MKN-7 cells, respectively. CAFs overexpressing a podoplanin mutant, lacking the cytoplasmic domain, had significantly reduced invasive capacity, compared to CAFs overexpressing wild-type podoplanin, and it also reduced the number of invading MKN-7 cells significantly. When HSC44PE cells, and CAFs were co-cultured, changes in the podoplanin expression in CAFs similarly altered the invasive capacity of CAFs, but it did not affect the number of invading HSC44PE cells. Conclusions These results indicate that in presence of CAFs, gastric cancer cells exhibit both CAF-dependent and -independent modes of invasion, the determinants of which may depend on the intrinsic properties of the gastric cancer cells.

Understanding the biological phenomena in model organisms typically relies on laboratory studies. However, the ecological validity of these findings is often uncertain when natural behaviors remain understudied. The medaka ( Oryzias latipes ) is a widely used model in reproductive and behavioral research; however, the timing of spawning in natural settings has rarely been directly observed. Recent fieldwork has suggested that medaka spawn several hours before sunrise, in contrast to the common assumption in laboratory-based studies that spawning occurs within an hour before or after exposure to light. In this study, we conducted continuous 24 h video recordings of medaka pairs under controlled laboratory conditions (14 L:10D photoperiod) to quantify diel variations in courtship and spawning behavior. Spawning occurred mostly between 08:00 and 11:00, peaking immediately after lights were turned on (08:00). Courtship behavior began during the dark period, increased before lights-on, and peaked between 07:00 and 09:00. These results exhibited a consistent delay of 3–4 h compared to (semi-)natural conditions. Our results highlight the influence of environmental conditions on reproductive timing in medaka. The temporal shifts observed in this study underscore the importance of incorporating natural temporal dynamics into experimental protocols to ensure accurate behavioral studies with model organisms.

Hansenula mrakii killer toxin resistant gene 1 ( HKR1 ) is an intronless, single-exon gene that encodes Hkr1, the signaling mucin of the budding yeast Saccharomyces cerevisiae . HKR1 overexpression confers S . cerevisiae cells with resistance to the HM-1 killer toxin produced by the killer yeast Hansenula mrakii (currently known as Cyberlindnera mrakii ). Hkr1 comprises multiple functional domains and participates in several signal transduction pathways, including the high-osmolarity glycerol (HOG) pathway, the cell wall integrity (CWI) mitogen-activated protein (MAP) kinase pathway, and the filamentation MAP kinase pathway; Hkr1 also controls bud-site selection. In this study, we identified a cryptic promoter in the HKR1 exon that regulates the transcription of a shorter transcript encoding a truncated form of Hkr1. This shorter protein still conferred resistance to the HM-1 killer toxin, suggesting that this cryptic promoter helps carry out Hkr1-mediated signal transduction efficiently by producing a specific Hkr1 domain with functions as a signaling messenger. Notably, reporter assays using the fluorescent protein gene mUkG1 and the β-galactosidase gene lacZ revealed that the transcriptional activity of this cryptic promoter was modulated by its upstream sequence within the single exon. Hkr1 thus differs from other signaling mucins, whose active C-terminal fragments are generated by post-translational processing, whereas the active C-terminal fragment of Hkr1 is generated by transcription from the exonic promoter. These findings describe a previously unknown example of functional diversification from a single gene, especially for a gene encoding a multidomain, multifunctional protein such as Hkr1.

Low-dimensional van der Waals materials have been extensively studied as a platform with which to generate quantum effects. Advancing this research, topological quantum materials with van der Waals structures are currently receiving a great deal of attention. Here, we use the concept of designing topological materials by the van der Waals stacking of quantum spin Hall insulators. Most interestingly, we find that a slight shift of inversion centre in the unit cell caused by a modification of stacking induces a transition from a trivial insulator to a higher-order topological insulator. Based on this, we present angle-resolved photoemission spectroscopy results showing that the real three-dimensional material Bi 4 Br 4 is a higher-order topological insulator. Our demonstration that various topological states can be selected by stacking chains differently, combined with the advantages of van der Waals materials, offers a playground for engineering topologically non-trivial edge states towards future spintronics applications. Angle-resolved photoemission evidence for a three-dimensional higher-order topological insulator is presented. This work demonstrates that stacking configurations can be utilized to realize different topological phases.

Control of the phase transition from topological to normal insulators can allow for an on/off switching of spin current. While topological phase transitions have been realized by elemental substitution in semiconducting alloys, such an approach requires preparation of materials with various compositions. Thus it is quite far from a feasible device application, which demands a reversible operation. Here we use angle-resolved photoemission spectroscopy and spin- and angle-resolved photoemission spectroscopy to visualize the strain-driven band-structure evolution of the quasi-one-dimensional superconductor TaSe 3 . We demonstrate that it undergoes reversible strain-induced topological phase transitions from a strong topological insulator phase with spin-polarized, quasi-one-dimensional topological surface states, to topologically trivial semimetal and band insulating phases. The quasi-one-dimensional superconductor TaSe 3 provides a suitable platform for engineering the topological spintronics, for example as an on/off switch for a spin current that is robust against impurity scattering. Angle-resolved photoemission spectroscopy is used to track the evolution of the electronic band structure of TaSe 3 across a strain-driven topological phase transition.

Mechanisms of hepatitis B virus (HBV) reactivation after hepatitis C virus (HCV) elimination by direct-acting antiviral (DAA) treatment in HBV/HCV-co-infected patients remain unclear. We examined RIG-I-like helicase (RLH) pathway activation by HBV mono-infection, HCV mono-infection or HBV/HCV co-infection and interference between HBV and HCV in primary human hepatocytes. Interference between HBV and HCV and HBV reactivation after DAA treatment in humanized-liver mice were assessed. HCV infection activated RLH pathway, as evidenced by RIG-I, ISG15 and ISG56 expression induction; HBV caused only RIG-I induction in vitro . RLH activation was also found in HBV/HCV-co-infected cells, and HBV replication were suppressed in HBV/HCV-co-infected than in HBV-mono-infected cells. siRNA-mediated double knockdown of ISG15 and ISG56 increased HBV replication in HBV/HCV-co-infected cells. HCV infection activated RLH pathway and suppressed HBV replication in humanized-liver mice. Subsequent elimination of HCV by DAA administration downregulated RLH pathway and upregulated HBV replication in mice. RLH pathway was activated in livers of chronic hepatitis C patients compared to those of chronic hepatitis B or non-B, non-C patients. The RLH pathway activation was downregulated by HCV elimination. In conclusion, HCV infection activated RLH pathway and suppressed HBV replication in human hepatocytes. HCV elimination upregulated HBV replication, probably through RLH pathway downregulation.

This algorithm was issued for the appropriate use of drugs for the treatment of type 2 diabetes mellitus in Japan. The revisions include safety considerations, fatty liver disease as a comorbidity to be taken into account and the position of tirzepatide.

The Japan Diabetes Society (JDS) adopted a sweeping decision to release consensus statements on relevant issues in diabetes management that require updating from time to time and launched a “JDS Committee on Consensus Statement Development.” In March 2020, the committee’s first consensus statement on “Medical Nutrition Therapy and Dietary Counseling for People with Diabetes” was published. In September 2022, a second consensus “algorithm for pharmacotherapy in people with type 2 diabetes” was proposed. In developing an algorithm for diabetes pharmacotherapy in people with type 2 diabetes, the working concept was that priority should be given to selecting such medications as would appropriately address the diabetes pathology in each patient while simultaneously weighing the available evidence for these medications and the prescribing patterns in clinical practice in Japan. These consensus statements are intended to present the committee’s take on diabetes management in Japan, based on the evidence currently available for each of the issues addressed. It is thus hoped that practicing diabetologists will not fail to consult these statements to provide the best available practice in their respective clinical settings. Given that the persistent dual GIP/GLP-1 receptor agonist tirzepatide was approved in April 2023, these consensus statements have been revised 1) . In this revision, specifically, tirzepatide was added to the end of [likely involving insulin resistance] of “Obese patients” in Step 1: “Select medications to address the diabetes pathology involved” in Fig.  2 . While the sentence, “Insulin insufficiency and resistance can be assessed by referring to the various indices listed in the JDS ‘Guide to Diabetes Management.’ was mentioned in the previous edition as well, “While insulin resistance is analogized based on BMI, abdominal obesity, and visceral fat accumulation, an assessment of indicators (e.g., HOMA-IR) is desirable” was added as information in order to more accurately recognize the pathology. Regarding Step 2: “Give due consideration to safety,” “For renal excretion” was added to the “Rule of thumb 2: Avoid glinides in patients with renal impairment.” The order of the medications in “rule of thumb 3: Avoid thiazolidinediones and biguanides in patients with heart failure (in whom they are contraindicated).” to thiazolidinediones then biguanides. In the description of the lowest part of Fig.  2 , for each patient failing to achieve his/her HbA1c control goal, “while reverting to step 1” was changed to “while reverting to the opening” and “including reassessment if the patient is indicated for insulin therapy” was added. In the separate table, the column for tirzepatides was added, while the two items, “Characteristic side effects” and “Persistence of effect” were added to the area of interest. The revision also carried additional descriptions of the figure and table such as tirzepatides and “Characteristic side effects” in the statement, and while not mentioned in the proposed algorithm figure, nonalcoholic fatty liver disease (NAFLD) is covered from this revision for patients with comorbidities calling for medical attention. Moreover, detailed information was added to the relative/absolute indication for insulin therapy, the Kumamoto Declaration 2013 for glycemic targets, and glycemic targets for older people with diabetes. Again, in this revision, it is hoped that the algorithm presented here will not only contribute to improved diabetes management in Japan, but will continue to evolve into a better algorithm over time, reflecting new evidence as it becomes available.

PurposeSN-38, a pharmacologically active metabolite of irinotecan, is taken up into hepatocytes by organic anion transporting polypeptide (OATP) 1B1. The effects of functional OATP1B1 521T>C on the pharmacokinetics of SN-38 remain controversial. Here, we prospectively examined the effects of OATP1B1 function on the area under the plasma total or unbound concentration–time curve (tAUC or uAUC) of SN-38 by assessing OATP1B1 521T>C and the plasma levels of endogenous OATP1B1 substrates, coproporphyrin (CP)-I and III, in cancer patients treated with irinotecan.MethodsWe enrolled cancer patients who were treated with an irinotecan-containing regimen and did not have severe renal failure. The total and unbound concentrations of SN-38 in the plasma were measured by high-performance liquid chromatography. AUC values were calculated and normalized to the actual irinotecan dose (AUC/dose). The OATP1B1 521T>C was analyzed by direct sequencing. Concentrations of the endogenous substrates in plasma before irinotecan treatment (baseline) were determined by liquid chromatography with tandem mass spectrometry.ResultsTwenty-two patients with a median estimated glomerular filtration rate of 74.8 mL/min (range 32.6–99.6) were examined. Both tAUC/dose and uAUC/dose were associated with the grade of neutropenia; however, they were not associated with OATP1B1 521T>C or baseline CP-I and III levels. It is worth noting that these baseline concentrations were significantly higher in patients with OATP1B1 521C, supporting functional changes in OATP1B1.ConclusionThe contribution of OATP1B1 activity to inter-patient variability in the systemic exposure to SN-38 is likely minimal in patients without severe renal failure.